Part 1 of 2
This May marks the 10th anniversary of the UW’s Coulter Translational Research Partnership in Biomedical Engineering, which has helped propel dozens of UW inventions from the lab toward clinical use. The UW was one of the first 10 universities to pioneer the program, which funds projects that address unmet clinical needs in patient care.
The Coulter program awards one-year, $100,000 grants to teams led by a UW faculty member and a clinician, and whose focus is on transferring their research into practice.
“We fund projects with a high likelihood of commercial success,” says Kathie Jordan, director of UW’s Coulter program. “Often they are in the early stage proof-of-concept category, and they are ready to move to next level.”
To date, the UW Coulter program has given $6.6 million in awards, which has resulted in some $780 million in follow-on funding from other sources, such as venture capitalists and research foundations, Jordan says.
To further support the success of the program awardees, Coulter partners with UW’s CoMotion (formerly the UW Center for Commercialization or C4C), Institute of Translational Health Sciences and the Washington Research Foundation.
Two of Coulter’s most recent successes come from the Department of Bioengineering, with technologies that have spun out into Nexgenia and another new company.
In this issue, BioE enews takes a look at the core technology that transferred to Nexgenia.
Nexgenia builds on BioE’s smart polymers and cell separation technology